In CML and GIST, translocation of the abl TK or activating KIT mutations not only provide mechanisms for upregulated proliferation and apoptosis resistance, they may also render the tumors entirely dependent on type III TK activity, and therefore susceptible to its inhibition. Here, SGCG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.